Nymox Pharmaceutical (NYMXF) AI Stock Analysis

• Market Cap: $4.79M
• Dividend Yield: N/A
• Average Volume (3M): 21.72K
• Price to Earnings (P/E): ―
• Beta (1Y): -383.12
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 94,540,140
• 10 Day Avg. Volume: 24,882
• 30 Day Avg. Volume: 21,717
• PEG Ratio: 0.04
• Price to Book (P/B): -1.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.60
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -6.12
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 22 Underperform
• Price Target: ―
• Action: N/A Date: 01/25/25
• Date: Action: N/A 01/25/25

Nymox Pharmaceutical faces substantial financial challenges as reflected by its persistent losses and negative equity. The technical analysis suggests a bearish trend, and the valuation indicates a lack of earnings, contributing to a low stock score.

Positive Factors

Focus on Unmet Medical Needs

Targeting unmet medical needs can lead to significant market opportunities if the company successfully develops effective treatments, particularly in aging-related conditions where demand is growing.

Lead Product Candidate

A focused development on a lead product candidate can streamline resources and increase the likelihood of achieving regulatory approval, potentially unlocking revenue streams through commercialization.

Potential Partnerships

Potential partnerships and licensing agreements can provide crucial funding and resources, enhancing the company's ability to bring products to market and share risks with established players.

Negative Factors

Persistent Financial Losses

Ongoing financial losses and negative equity indicate severe financial instability, which could hinder long-term operations and the ability to fund R&D activities necessary for future growth.

Negative Cash Flow

Negative cash flow suggests the company is burning cash without generating sufficient operational income, which may necessitate further financing and dilute shareholder value.

Lack of Revenue Growth

The lack of revenue growth and high negative margins highlight severe profitability issues, questioning the company's ability to sustain operations and achieve financial stability.

Nymox Pharmaceutical Business Overview & Revenue Model

Company Description

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

How the Company Makes Money

Nymox Pharmaceutical Corporation makes money primarily through the development and commercialization of its pharmaceutical products. The company generates revenue by advancing its drug candidates through clinical trials in the hope of achieving regulatory approval, which would allow it to market and sell these drugs. Key revenue streams include potential licensing agreements, partnerships with other pharmaceutical companies, and eventual product sales upon approval. Additionally, Nymox may receive milestone payments and royalties from partners who collaborate in the development and commercialization of its products. However, as a company focused on research and development, it may not have significant revenue until its products are approved and commercialized.

Nymox Pharmaceutical Financial Statement Overview

Summary

Nymox Pharmaceutical's financials reveal significant challenges, including persistent losses, negative equity, and cash flow issues, posing substantial risks without clear revenue or profit growth.

Income Statement

Nymox Pharmaceutical has consistently reported negative revenue, gross profit, and net income over the years, highlighting significant operational challenges. The absence of revenue growth combined with high negative EBIT and EBITDA margins indicates severe profitability issues and a lack of revenue generation capabilities.

Balance Sheet

The company has negative stockholders' equity, indicating more liabilities than assets, which is a significant financial risk. The debt-to-equity ratio is not calculable due to negative equity, but the consistent increase in total liabilities and reduction in assets suggests increasing financial instability.

Cash Flow

Nymox has consistently experienced negative operating cash flow, indicative of cash burn without sufficient operational income. Furthermore, free cash flow remains negative, reflecting a lack of capital sufficiency for reinvestment or debt reduction. The company relies heavily on financing activities to meet its cash requirements.

Breakdown	Dec 2024	Dec 2023	Mar 2023	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	―
Gross Profit	-1.00K	-11.00K	-12.00K	-12.00K	―
EBITDA	-4.26M	-8.77M	-6.52M	-12.49M	-11.71M
Net Income	-4.49M	-8.84M	-6.58M	-12.54M	-11.74M
Balance Sheet
Total Assets	654.00K	627.00K	1.63M	2.03M	4.93M
Cash, Cash Equivalents and Short-Term Investments	74.00K	70.00K	1.40M	830.00K	3.61M
Total Debt	0.00	750.00K	173.00K	391.00K	426.00K
Total Liabilities	7.43M	3.80M	2.11M	1.95M	2.20M
Stockholders Equity	-6.78M	-3.17M	-482.00K	83.00K	2.73M
Cash Flow
Free Cash Flow	-2.60M	-4.06M	-5.21M	-9.83M	-10.05M
Operating Cash Flow	-2.60M	-4.06M	-5.21M	-9.82M	-10.04M
Investing Cash Flow	0.00	-3.00K	0.00	-6.00K	-13.00K
Financing Cash Flow	2.60M	2.73M	5.78M	7.04M	8.42M

Nymox Pharmaceutical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.06
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NYMXF, the sentiment is Positive. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.61 is Neutral, neither overbought nor oversold. The STOCH value of 84.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NYMXF.

Nymox Pharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BOLT	48 Neutral	$8.18M	-0.36	-97.58%	―	-46.88%	34.83%
MBIO	45 Neutral	$7.23M	-5.07	-418.83%	―	―	98.58%
ACXP	45 Neutral	$7.39M	-0.87	-291.07%	―	―	61.10%
EVGN	43 Neutral	$6.89M	0.64	146.48%	―	-29.78%	88.96%
LYRA	41 Neutral	$2.31M	-0.48	-1032.82%	―	-59.21%	68.97%
NYMXF	22 Underperform	$4.79M	―	278.73%	―	―	―